Research Journal of Pharmaceutical, Biological and Chemical Sciences

Design and Charecterisation of Anastrazole Loaded Chitosan Nanoparticles by Ionotropic Gelation Method.

A Prameela Rani*[1], P Sivannarayana[2], K Abbulu[3], and V Saikishore[4]

[1]University College of Pharmaceutical Sciences, ANU, Guntur, Andhra Pradesh, India.
[2]Vishwabharathi College of Pharmaceutical Sciences, Perecherla, Guntur, Andhra Pradesh, India.
[3]Nova College of Pharmaceutical Education and Research, Hyderabad, Andhra Pradesh, India.
[4]Bapatla College of pharmacy, Bapatla, Andhra Pradesh, India.

ABSTRACT

Nanoparticulate drug delivery is a promising drug delivery system to a range of molecules to desired site specific action in the body. In this present work nanoparticles are prepared with positive group of amino group of chitosan with varying concentration based nanoparticles are loaded with anastrazole were prepared by with negative group of sodium tripolyphosphate by ionotropic gelation method. All these formulated nanoparticles are characterized for its particle size ,zeta potential ,drug entrapment efficacy and in-vitro release kinetics .The particle size of all these formulations were found to be 200,365,420,428 And 483.zeta potential of all formulations are -16.3±2.1 ,28.2±4.3,-10.38±3.6,-24.31±3.2 and 21.38±5.2.respectively. FT-IR studies indicated that there was no chemical interaction between drug and polymer and stability of drug. The *in-vitro* release behaviour from all the drug loaded batches was found to be zero order and provided sustained release over a period of 12 h by diffusion and swelling mechanism and The values of n and r^2 for coated batch was 0.731 and 0.979.Since the values of slope (n) lies in between 0.5 and 1 it was concluded that the mechanism by which drug is being released is a Non-Fickian anomalous solute diffusion mechanism,

Keywords: Anastrazole, chitosan, sodium tripolyphosphate, ionotropic gelation method.

*Corresponding author

INTRODUCTION

Nanoparticles are defined as particulate dispersions or solid particles with a size in the range of 10-1000nm. The drug is dissolved, entrapped, encapsulated or attached to a nanoparticle matrix. Depending upon the method of preparation, nanoparticles, nanospheres or nanocapsules can be obtained [1]. Therapeutic nanoparticle (NP) technologies have the potential to revolutionize the drug development process and change the landscape of the pharmaceutical industry [2-6]. The emergence of nanotechnology has made a significant impact on clinical chemotherapy in the last two decades. Advances in biocompatible nanoscale drug carriers such as liposomes and polymeric nanoparticles have enabled more efficient and safer delivery of a myriad of drugs in site specific drug delivery. Advantages in nanoparticle drug delivery, particularly at the systemic level, include longer circulation half-lives, improved pharmacokinetics and reduced side effects [7].

In cancer treatments, nanoparticles can further rely on the enhanced permeability and retention effect caused by leaky tumor vasculatures for better drug accumulation at the tumor sites. Recent studies have demonstrated that encapsulation of anti cancer drugs in a nanodroplet system would help in improving their cellular uptake and reducing their cytotoxic side effects [8-9].

Anastrozole 2,2_-[5-(1H-1,2,4-triazol-l-ylmethyl)-1,3-phenylene] bis(2-methyl propiononitrile) is a potent aromatase inhibitor and there is a need for an alternative to the oral method of administration to target cancer tissues, Anastrozole (Fig. 1), is a potent, third generation non-steroidal aromatase inhibitor for post-menopausal women in the treatment of breast cancer They have showed a great potential by serving as carriers for drugs, genes and imaging agents that would bind efficiently and selectively to specific targets on injured or neoplastic tissue. Nanocarriers may include liposomes, micelles, dendrimers and emulsification systems.[10].

Chitosan is the second most abundant natural polymer after cellulose obtained by deacetylation of chitin. Chitosan possess some ideal properties of polymeric carriers for nanoparticles such as biocompatible, biodegradable, nontoxic and inexpensive. These properties make chitosan a very attractive material as drug delivery carriers. Chitosan nanoparticles are prepared by the ionotropic gelation[11]. Based on the interaction between the negative groups of sodium tripolyphosphate (TPP) and Rendering positively charged amino (- NH2) and hydroxyl (-OH) groups, CS enables a high degree of chemical modification. [12].


Figure 1: Anastrazole(2,2_-[5-(1H-1,2,4-triazol-l-ylmethyl)-1,3-phenylene]bis(2-methyl propiononitrile))

MATERIALS AND METHODS

Anastrazole is a gift sample of celon laboratories Pvt. LTD, Hyderabad; chitosan is a gift sample of uniloids biosciences pvt. LTD., sodium tri polyphosphate is purchased from LOBA CHEMIE PVT LTD and All other chemicals solvents were in analytical grade.

Preparation of nanoparticles by Ionotropic gelation:

Anastrazole nanoparticles are prepared by ionic cross linking of chitosan solution with Tri poly phosphate (TPP) anions. Solutions were prepared by dissolving various concentrations of Chitosan (1-5mg/ml) and Trypolyphosphate (5ml of 0.25% W/V) in aqueous solution of acetic acid (2%v/v), and in double distilled water respectively. The nanoparticles were prepared in 20 different combinations of polymer and cross linking agent as per the composition range specified. Chitosan nanoparticles were spontaneously formed by the cross linking chitosan and tripolyphosphate under magnetic stirring at room temperature, while 8ml TPP aqueous solution was added drop wise into 20ml Chitosan solution containing 10 mg of Anastrazole using ethanol as a cosolvent. The stirring was continued for about 1hr. The resultant nanoparticles suspensions were centrifuged at 20000x g for 1 hr using REMI C24 centrifuge [13]. Out of which 5 formulations were found to be the better ones to investigate further and to reproduce a consistent formulation as shown in table-1

Table-1: Formulation ratios of Drug-chitosan-Sodium tripolyphosphate

Batch code	Amount of drug (mg/ml)	Conc. of chitosan(mg/ml)	Conc. of cross linliking agent(0.25 % W/V)
AN-IG 1	10	1	5ml
AN-IG 2	10	2	5ml
AN-IG 3	10	3	5ml
AN-IG 4	10	4	5 ml
AN-IG 5	10	5	5ml

FTIR study:

FTIR studies between anastrazole and the excipients were carried out to find interactions among the drug and polymers. Peaks of pure drug and combination with the polymer were checked for compatibility between them.

Particle size, Morphology and zetapotential:

The chitosan nanoparticles were observed with BECKMAN COULTER(Version 2.21 / 2.03) 6610LV . It was photographed using scanning electron gun operated with accelerating voltage of 0.3-30KV with a pre-centered tungsten hairpin filament shape and size were characterized simultaneously [14].

Surface Charge Determination:

The zeta potential of the chitosan nanoparticles was measured by using a BECKMAN COULTER (Version 2.21 / 2.03) at 90° scattering angle recorded for 90 seconds. The sample was distributed in the proper suspending medium, specifically an aqueous solution of NaCl (0.9% w/v), filtered (0.2 µm) double-distilled water[15].

Percentage Yield:

The nanoparticles production yield was calculated by gravimetry. Fixed volumes of nanoparticles suspensions were centrifuged by cooling centrifuge (16,000×g, 1hr, 15 ºC) and sediments were dried. The process yield was calculated as follows.

$$percentage\ yeild = \frac{nanoparticles\ weight}{total\ solidweight} \times 100$$

Drug entrapment efficacy:

The entrapment efficiency of the nanoparticles was analyzed by gravimetric analysis (mass balance). The drug trapped in chitosan nanoparticles and the free drug, un entrapped drug was estimated to know total amount of the drug entrapped. The drug present in the formulated was extracted from the formulation and then analysed for the drug content. A known volume of the nanosuspension was filtered through 0.22µm Whatmann filter paper. To the sediment obtained 2% of sodium citrate was added and centrifuged at 1000rpm for 15 min, to damage the chitosan crosslinks. Add 4% of acetic acid solution and till the sediment forms a clear solution. 5ml of methanol was taken into chitosan solution and vortexed for 10 min, colloidal solution was estimated under UV spectrophotometer at 221 nm [16]. The supernatant was also estimated as well to know the amount of the drug unentrapped.1ml of the methanol was added to 1ml of supernatant solution and filtered through 0.22µm filter and absorbance at 221 nm was noted under UV spectrophotometer.

***In vitro* release study:**

A franz diffusion cell was used to monitor Anastrazole release from the nanoparticles. The receptor phase was 2:10 ratios of methanol and phosphate buffered saline (PBS, pH 7.4) respectively thermostatically maintained at 37°C, with each release experiment run in triplicate[1]. Dialysis membrane with molecular weight cut off 12,000 to 14000 Daltons was used to separate receptor and donor phases. The latter consisted suspension of nanoparticles containing Anastrazole 1 mg mixed for 5 seconds to aid re-suspension in Phosphate Buffer Solution. Samples (1ml) from the receptor phase are taken at time intervals and an equivalent volume of phosphate buffer solution replaced into the receiver compartment. Diffusion of Anastrazole into the receptor phase was evaluated spectrophotometrically.

RESULTS AND DISCUSSION

Preformulation Drug Excipient Compatibility Studies

The FT-IR graph peaks of anastrazole are compared to the peaks noted from the official compendium. The FT-IR studies of formulation shown to have same peaks as the pure drug which confirms the integrity of the compound which can be concluded that the drug not prone to have any interaction with the excipients. From figure-2.

Particle size, Morphology and zetapotential:

Morphology study of the nanoparticles prepared by ionotropic gelation technique were found be spherical with good structural composition having a definite boundary as shown in the (figure-3) The average particle sizes were found to for all the formulations shown in (Table-2). It was observed that the formulation with lower polymer and crosslinking agent no formation of particulate system was found. The formulations at particular ratio a proportional increase in the concentration increased size of the nanoparticles.


Figure-3: SEM image of anastrazole loaded chitosan nanoparticles by ionotropic gelation method.

Determination of Surface Charge:

The nanoparticles prepared are maintained at ambient pH and temperature to prevent the degradation of the formulation. However the crosslinking agent being proton rich have influence on the zeta potential. (Table-2).

Entrapment Efficiency:

The entrapment efficacy of the drug in to the formulations is analysed by the gravimetric (mass balance analysis) which shows the results of each formulations. formulation with higher chitosan concentrations was found to have more entrapment efficacy entrapping 43±2.90 % of the drug for AN-IG -1.

Chitosan unique molecular geometry plays an important role in the drug entrapment efficacy. Most of the drug having positive charge is more suitable for the loading of drug into the chitosan network. The cationic drug Anastrazole is barely difficult task to have good entrapment. Interestingly this major hurdle is solved by the method of preparation. (Table-2)

In Vitro Release Study:

In vitro studies of optimized chitosan nano formulations were carried out for release pattern across cellophane membrane. The release patterns of AN-IG 1, AN-IG 2, AN-IG 3,.AN-IG 4 and AN-IG 5 are 100.0 ,99.2 , 99.29 , 86.6 and 83.8 respectively (Table -3)(graph-1). It was quite evident from the release profiles that show required drug release through nanoparticles for control release of 10 hours and AN-IG 1 was found to be good and best formulation and further research studies. in AN-IG 2 shows 99.2% of drug release for 10 hr and AN-IG 3, AN-IG 4 & AN-IG 5 are release 12 hrs because the polymer proportions increases.

Study of Release Kinetics:

The results of In vitro release profile obtained from all the formulations were plotted to know the mechanism of drug release (graph-3,4,5). The data were treated according to zero order release, first order release, higuchi's and korsemeye peppa's model equation. The release rate kinetics data for all the other equation can be seen in table - 4.

The equation, which is used to describe drug release mechanism, is:

$$m_t/m_8 = kt^n$$

Where, m_t / m_8 is the portion of drug release't' is the release time 'k' is the constant. K dictates the properties of the macromolecular polymer system. 'n' is the release exponent indicative of the mechanism of release. The values of n and r^2 for coated batch was 0.792 and 0.985.Since the values of slope (n) lies in between 0.5 and 1 it was concluded that the mechanism by which drug is being released is a Non-Fickian anomalous solute diffusion mechanism, that is, drug release during *in vitro* drug release may be controlled by all diffusion and swelling mechanism.

CONCLUSION

In this research work anastrazole nanoparticles are prepared by ionotropic gelation and emulsification crosslinking. The nanoparticles prepared by the Ionotropic gelation technique using chitosan as polymer and trypolyphosphate as cross linking agent were found to be nano range with acceptable physical and chemical natures. Based on percentage yield, drug entrapment efficiency, particle size morphology, zeta potential and *in vitro* release, formulation AN-IG 1(with polymer crosslinking agent ratio 1:5) was found to be the optimal formulation to sustain the drug release effectively in 10hr it is quite evident for further research (transdermal patch) to release drug in 24hrs.

Table 1: Formulation ratios of Drug-chitosan-Sodium tripolyphosphate

Batch code	Amount of drug (mg/ml)	Conc. of chitosan(mg/ml)	Conc. of cross linliking agent(0.25 % W/V)
AN-IG 1	10	1	5ml
AN-IG 2	10	2	5ml
AN-IG 3	10	3	5ml
AN-IG 4	10	4	5 ml
AN-IG 5	10	5	5ml

Table 2: Particle Size, Zeta Potential, and Entrapment Efficiency of Chitosan Nanoparticles prepared by ionotropic gelation

Formulations	Average Particles size (nm)	Zeta potential mV	Entrapment efficiency %
AN-IG1	200±15.6	-16.3±2.1	43±2.90
AN-IG 2	365±17.9	-28.2±4.3	48±3.12
AN-IG 3	420±23.6	-10.38±3.6	69±1.63
AN-IG 4	428±20.4	-24.31±3.2	73±3.45
AN-IG 5	483±23.5	-21.38±5.2	79±3.53

Table 3: In vitro drug release of anastrazole loaded chitosan nanoparticles

TIME	AN-IG 1	AN-IG 2	AN-IG 3	AN-IG 4	AN-IG 5
0	0	0	0	0	0
1	19.5	15	13.0	11.9	11.1
2	30.1	29	28.8	26.8	25.4
4	52.5	50.1	42.8	29.6	28.2
6	71.8	68.9	55.5	40.0	37.4
8	88.7	86.3	74.0	61.4	60.4
10	100	99.2	89.4	71.1	69.8
12	-	-	99.29	86.6	83.8

Table 4: Drug Release kinetics of, zero, First order, Higuchi & Peppas plot, *n* values of selected formulations prepared by ionotropic gelation

Formulations	Zero order	First order	Higuchi	Peppas	n-values
AN-IG 1	0.979	0.960	0.973	0.997	0.731
AN-IG 2	0.979	0.965	0.965	0.996	0.818
AN-IG 3	0.985	0.933	0.964	0.989	0.792
AN-IG 4	0.978	0.915	0.928	0.957	0.744
AN-IG 5	0.976	0.928	0.922	0.953	0.763

ANU COLLEGE OF PHARMACEUTICAL SCIENCES, ACHARYA NAGARJUNA UNIVERSITY


D:\IR DATA\2   ANASTRAZOLE   SOLID   4/27/2013

ANU COLLEGE OF PHARMACEUTICAL SCIENCES, ACHARYA NAGARJUNA UNIVERSITY

D:\IR DATA\6   ANAS+ACECLO+CHI+TPP   SOLID   4/27/2013

Figure 2

$y = 0.027x + 0.009$

$R^2 = 0.999$

**Graph 1: Calibration curve of anastrazole**

Graph 2: Drug Release Profiles of Nanoparticles prepared by ionotropic gelation

Graph 3: First Order kinetics of Nanoparticles prepared by ionotropic gelation

Graph 4: Peppas plot for the Nanoparticle prepared by ionotropic gelation

Graph 5: Higuchi plot of Nanoparticles prepared by ionotropic gelation

REFERENCES

[1] Nanoparticles – A Review, VJ Mohanraj and Y Chen, Trop J Pharm Res 2006; 5 (1), 561-573.

[2] Allen TM, Cullis PR. Science 2004; 303: 1818–1822.

[3] Wagner V, Dullaart A, Bock A-K, Zweck A. Nat Biotechnol 2006; 24(10):1211–1217.

[4] Farokhzad OC, Langer R. ACS Nano 2009; 3(1):16–20.

[5] Petros RA, DeSimone JM. Nat Rev Drug Discov 2010; 9(8):615–627.

[6] Shi J, Votruba AR, Farokhzad OC, Langer R. Nano Lett 2000; 10(9):3223–3230.

[7] Davis ME, Chen ZG, Shin DM. Nat Rev Drug Discov 2008; 7(9), 771–782.

[8] Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Clin Pharmacol Ther 2008; 83(5), 761–769.

[9] Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nat Nanotechnol 2007; 2(12), 751–760.

[10] Geisler J, King N, Dowsett M, Ottestad L, Lundgren S, Walton P, Kormeset PO, Lonning, PE. Br J Cancer 74, 1286–1291.

[11] Rajath othayoth et al., Int J Mech Eng Robot 2013:1(1).

[12] Yateendra et al., Int J Pharm Pharm Sci; 4(4):244-248.

[13] Simar PK, Rekha Rao, Afzal Hussain, Sarita Khatkar. J Pharm Sci Res 2011; 3(5): 1227-1232.

[14] Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. J Appl Polym Sci 1997; 63: 125–132.

[15] Sangeetha S, Harish G, Malay Samanta K. Int J Pharm Bio Sci 2010; 1(2).

[16] Kumar et al., Int Jf Adv Pharm Sci 2010;1:329-333.